Home loan banks drop objection to $8.5B settlement
Lawyers for the Federal Home Loan Banks of Boston, Chicago and Indianapolis on Wednesday told a New York Supreme Court judge they are withdrawing from the case against Bank of America Corp.
Lawyers for the Federal Home Loan Banks of Boston, Chicago and Indianapolis on Wednesday told a New York Supreme Court judge they are withdrawing from the case against Bank of America Corp.
Economists and politicians on both sides of the aisle have argued for years that streamlining government in Indiana could save millions of dollars, but vested interests and fear of change have stymied real reform.
The National Collegiate Athletic Association lost a bid to dismiss antitrust claims in a lawsuit brought by ex-student athletes over the use of their images and likenesses on television and in video games.
Strong demand for space in Simon’s outlet malls helped boost occupancy at its U.S. properties to 95.5 percent, up from 94.6 percent a year earlier.
The heads of WellPoint Inc., Aetna Inc. and at least 10 other insurers met with the Obama administration Wednesday to discuss correcting flaws in how data from the U.S. health-care marketplaces is transferred to the companies.
Health insurance execs, including WellPoint Inc. CEO Joseph Swedish, will meet with top White House officials Wednesday as the president seeks to contain political damage from the disastrous rollout of Obamacare.
The Indianapolis-based operator of radio stations expects free cash flow after capital expenditures to be about $14 million this year, said CEO Jeffrey Smulyan.
When Peyton Manning plays, ticket prices double on the secondary market and more people watch the game on television. He has as much influence with consumers as Bill Gates and actor Tom Hanks, a celebrity marketing expert says.
Indianapolis-based training firm Adayana Inc. said it sought Chapter 11 bankruptcy reorganization this week after two years of unsuccessfully trying to restructure its debts out of court.
Simon Property Group directors improperly refused to let shareholders vote on changes to the company’s executive-compensation plan that resulted in a $120 million stock award to CEO David Simon, investors’ lawyers argued Monday in court.
Indianapolis Colts quarterback Andrew Luck got an equity stake to join the sports advisory board of MC10, a technology startup that released its first commercial product in July.
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
Jeff Kessler, an attorney who helped bring free agency to the National Football League, is about to focus on the unpaid athletes who generate more than $16 billion in college sports television contracts.
Markets on Tuesday weren’t fazed by the the first partial government shutdown in 17 years. Open enrollment for Obamacare exchanges helped WellPoint shares.
Indigo Partners LLC, led by veteran airline executive William Franke, has agreed to buy Frontier Airlines from Indianapolis-based Republic Airways Holdings Inc. for $36 million in cash. The total value of the transaction is $145 million including debt.
Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin.
Team officials have not released details, but the contract is reported to be for five years and worth $80 million-plus.
Simon Property Group Inc. is selling 750 million euros ($1 billion) of seven-year securities as the yield discount to U.S. dollar notes approaches the widest in more than 4-1/2 years.
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.